Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasafytol in Hospitalized COVID-19 Patients
NCT04844658Completed
- Sponsor
- Tilman
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Tilman. Primary endpoints: Improvement of clinical condition of the patient defined by the COVID-19 WHO ordinal Outcomes score, Duration (days) of hospitalization at Day 14 and 8 more. Started Feb 2021; status: completed.
Beyond the preview
Go deeper on NCT04844658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844658.